Business
UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
Conference Call and Webcast Scheduled for Thursday, August 10, 2023 at 10:00 AM ET PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a
About this update from Urogen Pharma Ltd.
[{"type":"text","content":"\nConference Call and Webcast Scheduled for Thursday, August 10, 2023 at 10:00 AM ET\n\n\n PRINCETON, N.J.--(BUSINESS WIRE)--\nUroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2023 financial results on Thursday, August 10, 2023, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.\n\n\nA live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.\n\n\nAbout UroGen Pharma Ltd.\n\n\nUroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product Jelmyto® (mitomycin) for pyelocaliceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, New Jersey with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter,@UroGenPharma.\n\n\nJelmyto®, RTGel® and UroGen® are registered trademarks of UroGen Pharma Ltd.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230802943779/en/\n\nINVESTOR CONTACT:\nVincent Perrone\[email protected]\n(609) 460-3588\n\nMEDIA CONTACT:\nCindy Romano\[email protected]\n(609) 460-3583\n\n\nSource: UroGen Pharma Ltd.","length":3906,"tagName":"div"}]